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INTRODUCTION
Drug resistance is a major obstacle in the successful treat-
ment and an important cause of death in acute leukemia. Such
resistance may be present before begining treatment or may
develop during chemotherapy. Drug resistance that extends
to structurally and functionally unrelated drugs is termed
multidrug resistance (MDR) (1). 
Several molecular biological mechanisms have been identi-
fied as being associated with MDR (2). P-glycoprotein (PGP),
also named P-170, is a product of the multidrug resistance
1 gene (MDR1) and is an ATP-dependent pump capable of
expelling drugs out of cancer cells (3, 4). PGP is a transmem-
brane glycoprotein conferring cross-resistance to a variety of
mechanistically and structurally unrelated cytotoxic drugs,
such as anthracyclines, taxanes, vinca alkaloids and epipodo-
phyllotoxins (5). Another protein, the multidrug resistance-
related protein (MRP), is structurally similar to PGP and be-
longs to the same transmembrane transporter superfamily
(6). The substrate specificity of MRP is similar to but more
limited than that of PGP, and its normal physiological role
may be detoxification of intracellular oxidants (5). In addition
to these two proteins, a 110 kDa protein has been identified
in a PGP-negative MDR lung cancer cell line. This protein
was termed the lung resistance protein (LRP) and acts as a
major vault protein in humans (7). Despite the identification
of these proteins, the pathways that result in drug resistance
in leukemic cells remain largely uncharacterized. New infor-
mation regarding drug resistance mechanisms is likely to in-
crease the chances of cure either through development of new
drugs or by means of strategies that may modulate or reverse
resistance (8). While drug resistance gene expression has been
studied in acute leukemia (9-12), the value of MDR1, MRP
and LRP gene expression as independent predictors of treat-
ment success is still controversial. 
In the present study, we investigated whether outcomes in
acute leukemia patients were associated with MDR1, MRP
and LRP mRNA expression.
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Prognostic Significance of Multidrug Resistance Gene 1 (MDR1), 
Multidrug Resistance-related Protein (MRP) and Lung Resistance 
Protein (LRP) mRNA Expression in Acute Leukemia 
The prognostic significance of multidrug resistance (MDR) gene expression is con-
troversial. We investigated whether multidrug resistance gene 1 (MDR1), multidrug
resistance-related protein (MRP) and lung resistance protein (LRP) mRNA expres-
sion are associated with outcomes in acute leukemia patients. At diagnosis we exam-
ined MDR1, MRP and LRP mRNA expression in bone marrow samples from 71
acute leukemia patients (39 myeloid, 32 lymphoblastic) using nested RT-PCR. The
expression of each of these genes was then expressed as a ratio in relation to  -
actin gene expression, and the three genes were categorized as being either 0, 1+,
2+ or 3+. MDR1, MRP and LRP mRNA expression was detected in 23.9%, 83.1%
and 45.1 %, respectively. LRP mRNA expression was significantly associated with
resistance to induction chemotherapy in acute leukemia patients, and in the AML
proportion (p=0.02 and p=0.03, respectively). MRP and high MDR1 mRNA expres-
sion was associated with poorer 2-yr survival (p=0.049 and p=0.04, respectively).
Patients expressing both MRP and LRP mRNA had poorer outcomes and had worse
2-yr survival. The present data suggest that MDR expression affects complete remis-
sion and survival rates in acute leukemia patients. Thus, determination of MDR gene
expression at diagnosis appears likely to provide useful prognostic information for
acute leukemia patients.
Key Words : Genes, MDR; Multidrug Resistance Gene 1; P-Glycoprotein Multidrug Resistance-related Pro-
tein 1; lung resistance protein; Prognosis; Leukemia
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MATERIALS AND METHODS
Patients 
The study involved 71 patients (34 males and 37 females)
diagnosed with acute leukemia between January 1998 and
January 1999. The median age of the patients was 30 yr (ran-
ge, 3 months - 75 yr). Diagnosis and classification of acute
leukemia was made according to the French-American-British
(FAB) criteria and immunophenotype analyses. There were
39 acute myeloid leukemia (AML) and 32 acute lymphoblas-
tic leukemia (ALL) patients. Among 39 AML patients, eleven
patients had AML M1, 11 M2, 7 M3, 6 M4, 2 M5, 1 M6
and 1 M7. The patients were classified as being good progno-
sis group, intermediated prognosis group and poor progno-
sis group according to cytogenetic results. AML patients with
t(8;21), t(15;17) and inv (16) were defined as “good progno-
sis group”, patients with 5-, 7-, 5q-, 7q-, hyperdiploidy and
multiple chromosomal abnormality were defined as “poor
prognosis group”, and  the others were defined as the “interme-
diate prognosis group”. Among AML patients, eight patients
(t(8;21), 1; t(15;17), 7) were in good prognosis group, 20 (nor-
mal karyotype, 19; t(11;19), 1) in intermediate prognosis
group and 12 ( trisomy 8, 2; other complex abnormality, 10)
in poor prognosis group. Among ALL patients, two were in
good prognosis group, 11 in intermediate prognosis group
and 19 in poor prognosis group. The induction chemother-
apy regimen were cytarabine plus idarubicin (AI regimen) in
adult AML patients and vincristine, prednisone, daunorubi-
cin, L-asparaginase (VPDL regimen) in adult ALL patients.
Newly diagnosed childhood ALL patients were treated accord-
ing to Children’s Cancer Group (CCG) 1881, 1882, 1891 or
1901 protocols. Childhood AML patients were treated accord-
ing to BFM (Frankfurt Munster group) 83 protocols, includ-
ing cyclophosphamide and prednisone. Clinical information
was obtained by reviewing charts. 
Definition of disease phase and response
Complete remission (CR) was defined as a cellularity of
more than 20% with fewer than 5% blasts in the bone mar-
row (BM) after induction chemotherapy, and relapse as more
than 5% blasts in the BM. The CR rate was calculated only
using patients that underwent bone marrow analysis follow-
ing initial diagnosis (64 cases). 
Semiquantitative RT-PCR
Seventy one bone marrow aspirates collected in EDTA were
obtained at the initial diagnosis. A COR-L23/R cell line was
used as a positive control for MDR1 and LRP mRNA expres-
sion, and the HL60/Adr cell line for MRP mRNA expression.
Negative controls included deionized RNAase-free water, and
bone marrow aspirates obtained from patients with lympho-
ma without bone marrow involvement.  -actin mRNA am-
plification was used as an internal control.
Mononuclear cells were separated by density gradient cen-
trifugation using Ficoll-Hypaque within 3 hr after bone mar-
row aspiration. Total cellular RNA was extracted using the
RNeasy kit (Qiagen Inc., Valencia, CA, U.S.A.) according to
the manufacturer’s instructions. 
cDNA was synthesized using the First Strand cDNA Syn-
thesis Kit for RT-PCR (Behringer Mannheim Inc, Germany).
Total RNA (1  g) was reverse transcribed in 20  L reaction
mixture (2  L 10X Reaction buffer [100 mM Tris, 500 mM
KCL, pH 8.3 and 25 mM MgCl2], 10 mM each of four dNTPs,
1.6  g/ L random primers, 50 U/ L RNase inhibitor and 1
L AMV Reverse Transciptase). The reaction was performed
at 70℃ for 2 min and 42℃ for 60 min. MDR1, MRP and
LRP mRNA amplifications were performed after heating the
reaction mixture to 99℃ for 5 min. The first round of PCR
reactions involved 30 cycles of: 1 min denaturing at 94℃, 1
min annealing at 64℃ and 2 min extension at 72℃ using
a thermocycler (Perkin Elmer-Cetus, Wellesley, PA, U.S.A.).
The PCR reactions were carried out in a final volume of 50
L containing 2  g cDNA, 10 pg/ L of each primer, 0.4 U/ L
taq polymerase, 200  M of each dNTP, 5  L 10X buffer con-
taining 500 mM KCl, 100 mM Tris (pH 8.3) and 25 mM
MgCl2. The first round of PCR was followed by a second ro-
und of 20 cycles. Amplification of  -actin mRNA (20 cycle
PCR) was performed and the data obtained used to normalize
any variations between samples (e.g. differences in concen-
tration or quality of extracted RNA). PCR primer sequences
Target Direction Sequences of primer
MDR1 External Sense 5′ -CCAGTGGTGTTTTTAGGGTCATCA-3′
primers
Antisense 5′ -CCAAAGAGGCTCTGGATGAAAG-
TA-3′
Internal Sense 5′ -TGTTGTTGGTGTATTTTGTGCCATT-
primers AT-3′
Antisense 5′ -GTATCGGAGCCGCTTGGTGAGA-3′
MRP External Sense 5′ -TACACCGTGCTGCTGTTTGTCACT-3′
primers
Antisense 5′ -GTCTTGGTCATCGCCATCACA-3′
Internal Sense 5′ -ACTTCCACATCTGCTTCGTCAGTG-3′
primers
Antisense 5′ -ATTCAGCCACAGGAGGTAGAGA-
GC-3′
LRP External Sense 5′ -GTCTTCGGGCCTGAGCTGGTGT-
primers CG-3′
Antisense 5′ -CTTGGCCGTCTCTTGGGGGTCC-
TT-3′
Internal Sense 5′ -TTCTGGATTTGGTGGACG-3′
primers
-actin Antisense 5′ -ACTTCTCTCCCTTGACCA-3′
Sense 5′ -GTGGGGCGCCCCAGGCACCA -3′
Antisense 5′ -GTCCTTAATGTCACGCACGATTTC-3′
Table 1. RT-PCR primer sequences for MDR1, MRP, LRP and
-actin mRNA amplification
. .are shown in Table 1. PCR products were electrophoretically
separated on 2% agarose gels and visualized using ethidium
bromide staining. The gel was photographed with Polaroid
film (Fig. 1) and the film scanned into a computer (Sharp JX-
330, Japan) for analysis. For semiquantitative measurements
of mRNA, the relative ratios of MDR1, MRP or LRP mRNA
expression to  -actin mRNA expression was calculated using
ImageMaster software (Pharmacia, Sweden). Following the
determination of this ratio, MDR genes were classified as
either not expressed (0), weakly expressed (ratio 0-0.7=1+),
moderately expressed (ratio 0.7-1=2+), or strongly expressed
(ratio >1=3+). 
Statistics
Data were analyzed using chi square or Fisher exact tests.
Survival curves were plotted using the Kaplan-Meier method,
and differences were analyzed using log-rank tests. A p value
<0.05 was deemed to indicate a significant difference. All
statistical analyses were performed using SPSS version 11.5
(SPSS, Chicago, IL., U.S.A.).
RESULTS
Expression rates, levels of MDR mRNA and cytogenetic
results
We found that the proportion of acute leukemia patients
expressing MDR1, MRP and LRP mRNA was 23.9%, 83.1
% and 45.1%, respectively (Table 2). In terms of leukemia
categories, MDR1, MRP and LRP mRNA was expressed in
23.1%, 89.4% and 48.7% respectively of AML patients, and
in 25.0%, 75.0% and 40.6% respectively of ALL patients.
While fewer patients expressed MDR1 mRNA compared to
MRP and LRP mRNA, the rate of MDR1 mRNA expression
(3+) was higher than the rate of either MRP or LRP mRNA
high expression (3+) (Table 2). Univariate analysis showed
no correlation between cytogenetic results and MDR1, MRP
and LRP mRNA expression in AML and ALL patients.
Association of MDR1, MRP and LRP mRNA expression at
diagnosis with the rate of complete remission, relapse
and survival time
LRP mRNA expression at initial diagnosis was associated
with a lower CR rate after induction chemotherapy, with only
55.2% (16/29) of LRP-positive acute leukemia patients achi-
eving CR, compared to 82.9% (29/35) of LRP-negative pa-
tients achieving CR (p=0.02). Similarly, for AML patients,
47.1% (8/17) of LRP-positives achieved CR, while 82.4%
(14/17) of LRP-negatives achieved CR (p=0.03). MDR1 and
MRP mRNA expression appeared to have statistically no sig-
nificant effect on patient outcome following induction chemo-
therapy. However, MDR1 or MRP mRNA-positive patients
showed the tendency of lower CR rates than MDR1 or MRP-
negative patients (Table 3). MDR1, MRP or LRP mRNA
expression had no effect on relapse rates. The multivariate
logistic regression analysis of age, MDR mRNA expression
and cytogenetic results indicated that the MDR mRNA ex-
pression did not give significant effects on relapse and contin-
uous CR after induction chemotherapy.
Kaplan-Meier analysis showed that the median survival for
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Fig. 1. RT-PCR products following MDR1, MRP and LRP mRNA
amplification. Lane S, size marker; lane 1, MDR1-positive cell line
(band at 243 bp); lane 2, DW; lane 3, normal bone marrow; lane 4,
MDR1-positive patient; lane 5, MRP-positive line (bands at 575 and
420 bp); lane 6, DW; lane 7, normal bone marrow; lane 8, s-positive
patient; lane 9, LRP-positive cell line (band at 239 bp); lane 10,
DW; lane 11, normal bone marrow; lane 12, LRP-positive patient;
lane 13,  -actin (internal control, band at l66 bp). (DW=deionized
water (negative control)).
S    1    2    3    4   5    6    7    8   9   10  11  12  13   S
575 bp
420 bp
243 bp
166 bp
No.
Table 2. Semiquantitative MDR gene expression results in acute leukemia patients
MDR1
1+ 2+ 3+
(+)
(-)
MRP
1+ 2+ 3+
(+)
(-)
LRP
1+ 2+ 3+
(+)
(-)
(76.9) 1 (2.6) 5 (12.8) 3 (7.7)
39 30 9 (23.1)
(10.3) 20 (51.3) 14 (35.9) 1 (2.6)
4 35 (89.7)
(51.3) 11 (28.2) 8 (20.5) 0 (0.0)
20 32 (45.1)
(76.1) 3 (4.2) 11 (15.5) 3 (4.2)
71 54 17 (23.9)
(16.9) 38 (53.5) 20 (28.2) 1 (1.4)
12 59 (83.1)
(54.9) 19 (26.8) 13 (18.3) 0 (0.0)
39 32 (45.1)
(75.0) 2 (6.3) 6 (18.8) 0 (0.0)
32 24 8 (25.0)
(25.0) 18 (56.3) 6 (18.8) 0 (0.0)
8 24 (75.0)
(59.4) 8 (25.0) 5 (15.6) 0 (0.0)
19 13 (40.6)
Acute leukemia (%)
Acute myeloid
leukemia (%)
Acute lymphoblastic
leukemia (%)256 H.J. Huh, C.-J. Park, S. Jang, et al.
MRP-positive acute leukemia patients was 600 days, while
MRP-negative patients did not reach the median survival time.
There was a significant difference in the 2-yr survival between
these two groups (p=0.049) (Fig. 2). There was statistically
no prognostic significance for MDR1 (p=0.05) or LRP mRNA
(p=0.08) expression in acute leukemic patients in total, nor
for AML or ALL patients when analyzed separately. 
High level MDR1 mRNA expression was significantly
associated with poorer 2-yr survival in acute leukemia patients
(p=0.04) (Fig. 3), with all three such patients dying within
2 yr (20 days, 228 days and 405 days) of diagnosis. Among
these patients, two were diagnosed with adult AML and one
with childhood AML. Only one of these three patients achie-
ved CR after induction chemotherapy. 
While the survival time appeared to decrease with increas-
ing MRP and LRP mRNA expression levels, this observation
was not supported by statistical analysis. 
Outcome in acute leukemia patients expressing two
MDR genes
Double positivity for MDR1 and MRP mRNA was detect-
ed in 17 samples (23.4%), MDR1 and LRP mRNA in 15
(21.1%) and MRP and LRP mRNA in 31 (43.7%). MDR1
and LRP positive patients also showed positivity for MRP.
While 57.1% (16/28) of acute leukemia patients expressing
both MRP and LRP mRNA achieved CR, 80.6% (29/36)
of those not expressing both genes achieved CR (p=0.04). Ex-
pressing both MDR1 and MRP mRNA, or both MDR1 and
LRP mRNA had no significant influence on the CR rate after
induction chemotherapy. The median survival of MRP and
LRP-double positive patients was 405 days; the other patients
did not reach median survival. There was a significant differ-
ence in the 2-yr survival between the two groups (p=0.04).
Expressing both MDR1 and MRP mRNA, or MDR1 and
LRP mRNA had no negative impact on 2-yr survival. 
DISCUSSION
The present study indicates that MDR gene expression can
affect outcomes in acute leukemia patients. LRP gene expres-
sion at diagnosis appeared to be associated with resistance to
induction chemotherapy in acute leukemia patients. This was
not the case for MDR1 or MRP gene expression. For AML
patients, while over 80% of LRP-negative subjects achieved
CR, less than half of the LRP-positive subjects achieved CR
(p=0.03). Therefore, LRP mRNA expression was particular-
ly influential in outcomes following induction chemotherapy
in AML patients. This correlation between LRP expression
Positive Negative
Table 3. Relationship between MDR gene expression at acute leukemia diagnosis and complete remission (CR) and relapse rates after
induction chemotherapy
MDR1 MRP
Positive Negative
LRP
Positive Negative
*p value <0.05; CR, complete remission.
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Fig. 2. Relationship between MRP mRNA expression and 2-yr sur-
vival in acute leukemia patients.
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Fig. 3. Relationship between MDR1 mRNA expression levels and
2-yr survival in acute leukemia patients.
0
1+or 2+
3+
Acute leukemia  CR (%) 8/15 (53.3) 37/49 (75.5) 35/52 (67.3) 10/12 (83.3) 16/29 (55.2)* 29/35 (82.9)*
(n=71) Relapse (%) 2/8 (25.0) 12/37 (32.4) 11/35 (31.4) 3/10 (30.0) 7/16 (43.8) 7/29 (24.1)
Acute myeloid CR (%) 3/8 (37.5) 19/26 (73.1) 19/30 (63.3) 3/4 (75.0) 8/17 (47.1)* 14/17 (82.4)*
leukemia (n=39) Relapse (%) 1/3 (33.3) 8/19 (42.1) 8/19 (42.1) 1/3 (33.3) 4/8 (50.0) 5/14 (35.7)
Acute lymphoblastic CR (%) 5/7 (71.4) 18/23 (78.3) 16/22 (72.7) 7/8 (87.5) 8/12 (66.7) 15/18 (83.3)
leukemia (n=32) Relapse (%) 1/5 (20.0) 4/18 (22.2) 3/16 (18.8) 2/7 (28.6) 3/8 (37.5) 2/15 (13.3)MDR mRNA Expression in Acute Leukemia  257
and treatment outcome is consistent with suggestions that
chemosensitive leukemic cells have low LRP mRNA levels
in AML (10, 13).
Interestingly, it was reported that LRP mRNA expression
more strongly correlated with drug resistance than LRP pro-
tein expression (14). Sauerbrey et al. (15) suggested that LRP
overexpression might be a mechanism involved in childhood
ALL drug resistance. While the present data appeared to sug-
gest LRP-positive ALL patients showed a lower probability
for first remission, this observation was not supported statis-
tically. 
In AML patients, PGP/MDR1 expression was found to be
an independent prognostic variable associated with reduced
probability for achieving remission following conventional
anthracene-containing induction regimens, and in some re-
ports this expression was linked to inferior leukemia-free and
overall survivals (16-18). However, while our data appeared
to suggest that MDR1-positive AML and ALL patients had
low CR rates and poor 2-yr survivals, this observation was
not supported by statistical analysis. It may be that analysis
of a larger number of patients would provide the statistical
power for significance. The different sensitivities of the detec-
tion techniques may be responsible for the discrepant statis-
tical significance. However, three patients with strong MDR1
mRNA expression died within 2 yr, and high levels of MDR1
mRNA were significantly associated with poor 2-yr survival
in acute leukemia patients. Therefore, we need to consider
that patients with high MDR1 mRNA expression may have
poorer outcomes.
The reported proportion of patients positive for MDR gene
expression varies widely and appears to be related to the study
method employed and the patient characteristics of any par-
ticular study. In the present study, 83.1% of patients expre-
ssed MRP mRNA, and 2-yr survival in these patients was
less than that in MRP-negative patients (p=0.049). Although
some studies show MRP expression lacked prognostic power
(19, 20), others found it was predictive of poorer outcome (21). 
In the present study, MRP and LRP-double positive patients
showed reduced remission rates after induction chemothera-
py and poorer 2-yr overall survival compared to patients not
expressing both of these genes. Only two studies have previ-
ously attempted to determine the impact of simultaneous
expression of two MDR genes, and the conclusions drawn by
these studies were not consistent with each other (21, 22). 
The present study demonstrates that outcomes in acute
leukemia patients can vary depending upon expression of
MDR1, MRP and LRP mRNA. Simultaneous expression of
MRP and LRP mRNA correlated with a low CR rate and
poor survival. These results suggest that analysis of MDR gene
expression at diagnosis of acute leukemia may provide useful
prognostic information. Such data is also likely to assist in
determining the mechanisms underlying drug resistance.
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